117 related articles for article (PubMed ID: 10506607)
1. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.
Kurzrock R; Pilat S; Duvic M
J Clin Oncol; 1999 Oct; 17(10):3117-21. PubMed ID: 10506607
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin (Nipent) in T-cell lymphomas.
Kurzrock R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):64-6. PubMed ID: 10877055
[TBL] [Abstract][Full Text] [Related]
3. Therapy of T cell lymphomas with pentostatin.
Kurzrock R
Ann N Y Acad Sci; 2001 Sep; 941():200-5. PubMed ID: 11594574
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Tsimberidou AM; Giles F; Duvic M; Fayad L; Kurzrock R
Cancer; 2004 Jan; 100(2):342-9. PubMed ID: 14716770
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH; Hagemeister FB; Duvic M; Romaguera JE; Younes A; Jones D; Samuels B; Fayad LE; Pro B; Samaniego F; Sarris A; Goy A; McLaughlin P; Tong AT; Walker PL; Tiongson LP; Smith TL; Huh YO; Morimoto C; Rodriguez MA
Oncol Rep; 2003; 10(5):1513-8. PubMed ID: 12883733
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.
Greiner D; Olsen EA; Petroni G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):950-5. PubMed ID: 9204061
[TBL] [Abstract][Full Text] [Related]
9. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
10. Hemolytic-uremic syndrome induced by pentostatin in a patient with cutaneous T-cell lymphoma.
Antunes I; Magina S; Granjo E; Elíseo A; Lemos R; Barros MA; Mesquita-Guimarães J
Dermatology; 1999; 198(2):179-80. PubMed ID: 10325474
[No Abstract] [Full Text] [Related]
11. Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group.
Monfardini S; Sorio R; Cavalli F; Cerny TH; Van Glabbeke M; Kaye S; Smyth JF
Oncology; 1996; 53(2):163-8. PubMed ID: 8604244
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.
Cummings FJ; Kim K; Neiman RS; Comis RL; Oken MM; Weitzman SA; Mann RB; O'Connell MJ
J Clin Oncol; 1991 Apr; 9(4):565-71. PubMed ID: 2066753
[TBL] [Abstract][Full Text] [Related]
13. Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Ann Oncol; 1999 Dec; 10(12):1493-8. PubMed ID: 10643542
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with purine nucleoside analogs.
Foss FM
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):31-5. PubMed ID: 10887642
[TBL] [Abstract][Full Text] [Related]
15. Possible pentostatin-induced symptomatic hyponatremia.
Bruno JJ; Canada TW
Pharmacotherapy; 2007 Jan; 27(1):164-9. PubMed ID: 17192171
[TBL] [Abstract][Full Text] [Related]
16. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
Mercieca J; Matutes E; Dearden C; MacLennan K; Catovsky D
J Clin Oncol; 1994 Dec; 12(12):2588-93. PubMed ID: 7989933
[TBL] [Abstract][Full Text] [Related]
17. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
18. Long term outcome of patients with hairy cell leukemia treated with pentostatin.
Ribeiro P; Bouaffia F; Peaud PY; Blanc M; Salles B; Salles G; Coiffier B
Cancer; 1999 Jan; 85(1):65-71. PubMed ID: 9921975
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
